An investment firm founded in 2015 is actively supporting new healthcare companies in the USA and Canada. The firm is partnering with a New York-based firm to fund companies and assist those companies in scaling. The firm typically invests $250,000-$1.5 million, and while the firm focuses on companies interested in a “soft landing” in Western New York, the firm has the capacity to invest elsewhere as well.

The firm focuses on healthcare solutions that include a software component. Areas of interest include remote sensing, healthcare in the cloud, assistive devices, and remote sensing devices (e.g. Health IT).

The firm focuses on companies that have the capacity to become US government contractors. The firm supports their portfolio companies in bidding for contracts, and is able to work with both US and Canadian companies interested in becoming listed on the GSA Schedule.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with headquarters in Taiwan also has additional venture partners based in USA and multiple Asian countries. Based on National Development Fund in Taiwan, Taiwan Government matched 30% of the fund formed between local and international investors. The firm has over $100M AUM and its initial size of investment is in $1-6M range. However, the firm has the capacity to invest more in companies they identify as a strong fit. The firm is looking for companies globally but would prefer companies that have a Taiwan angle.

The firm is an opportunistic investor that currently considering Therapeutics, Medical Devices, Diagnostics, Biotechnology R&D, and Healthcare IT companies. The firm is open to many sectors in therapeutics but would prefer phases that past pre-clinical. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled device. The firm invest in any phases in medical devices and diagnostics especially in clinical. The firm looks into any indications except orphan disease.

The firm currently will invest in privately held companies only. The firm has no specific requirements for management team. The firm can participate as either lead or co-investor and generally requests a board seat or board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and developer of medical technologies is headquartered in Taipei, Taiwan with a USA subsidiary. With vertical integration of experienced medical professionals, talented engineers, and international infrastructure, the firm is dedicated to developing high value and high impact medical devices. The firm looks for new in-licensing or investment opportunities in cutting-edge medical device innovations from North America, Asia, and Europe, with no set cap on investment size.

Focusing on minimally invasive surgical devices and healthcare information technologies, the firm invests in companies at any stage of development, from ideation, early product design, prototyping, preclinical testing, clinical trials to commercialization. The firm prefers disease states with sizable patient population, including but not limited to cardiovascular or peripheral vascular disease, orthopedics, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery.

The firm is looking for collaborations with competent entrepreneurs, physicians, companies and investors and willing to lead and co-invest in med-tech companies to develop novel solutions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2007 with multiple offices globally has deep business expertise across USA and Asia and works with a close network of over 30 large Asian companies, which enables the firm to help portfolio companies beyond capital investment. The firm focuses on Series A financing rounds primarily in US startups with initial investment sizes ranging between $3-5M (USD) but will selectively participate in Seed and Series B rounds as well. The firm seeks to make 5-7 investments per year, and will selectively consider investment opportunities globally.

The firm invests in a wide range of technology subsectors, including consumer tech and enterprise solutions. In the life sciences/healthcare space, the firm is most interested in health IT/digital health companies including non-invasive health devices, data informatics and SaaS healthcare solutions. The firm is indication agnostic.

The firm seeks to invest in companies with strong potential in the US and Asia markets that could benefit from the firm’s value add-on. The firm prefers to act as the lead investor and have board representation, but is open to co-investing in select cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in Florida is currently making investments from its second fund, which is specifically focused on early commercialization stage medical device companies with at least one product on the market and in need of funding to grow sales and broaden their product offering. The firm seeks to allocate $250K to $3M (in equity or mezzanine) per company. The firm invests in companies that are based in the USA.

The firm seeks to invest in medical devices that provide solutions to unmet orthopedic, neurosurgical, and gastroenterology problems. The firm prefers Class I and II devices that are nearing or have regulatory approval.

The company must have at least one product on the market to be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-family office based in Canada has historically focused on the mining, oil and gas industries, but is beginning to become more involved with direct investments in the early stage healthcare space. Initial investments can range from $500k – $5M, but has a large network of family offices that they may syndicate with on larger deals. The group is flexible in terms of financing structures, and is open to straight equity in priced financing rounds as well as convertible notes, depending on the stage and specifics of the deal. The group has the capability to lead, but has no preference and will also co-invest as a syndicate, and is focused on companies in the U.S. and Canada.

The group is fairly new to the healthcare space and is primarily focused on the medtech and healthcare IT sectors, and is open to a variety of technologies/companies in these areas. The group has a specific interest in AI/big data applications in healthcare, and the primary screening criteria for all prospective companies being that the company have a very scalable business model. Further, the group looks for companies that have exhibited some sort of traction or customer support. In the medtech space, the group will look at medical devices pre-FDA approval on a secondary basis.

The group invests in companies in North America, but has no strict requirements for companies or management teams. The group does not require a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single-family office organization based in California is generally looking to make Seed and Series A investments in emerging life science companies. The firm can make investments ranging for $100,000 to $2 million and is currently interested in companies based throughout the US.

The firm is looking for companies in sectors of therapeutics, diagnostics and medical devices. The firm is generally open to all indications but has increased interests in ophthalmology and dermatology. The firm is focused on pre-clinical stage companies and is comfortable working with early university spinouts.

The firm is looking for privately held companies. The firm is open to working with firms that have incomplete management teams and has experience in helping form a team around an idea. The firm also has relationships with a CRO and can offer additional strategic value in addition to capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.